GSC The List

Post Reply
Forum Home > CBR - GPR55 / CB3 CANNABINOID RECEPTOR* > 2000-2014

[email protected]
Site Owner
Posts: 1174

Activated by l-α-lysophosphatidylinositol (LPI), and to a lesser extent possibly by THC, CBD,O-1602, PEA, 2-AG, Anandamide, Virodhamine Cannabinoid Receptor Ligands (full – undated)

Evolutionary Origins of the Endocannabinoid System. (abst – 2006)

GPR55: a new member of the cannabinoid receptor clan? (full – 2007)

The orphan receptor GPR55 is a novel cannabinoid receptor. (full – 2007)

GPR55 and the vascular receptors for cannabinoids. (full – 2007)

The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. (full – 2007)

GPR55 and the vascular receptors for cannabinoids. (full – 2007)

GPR55 is a novel cannabinoid receptor (full – 2007)

Novel cannabinoid receptors (full – 2007)

CB1 receptors mediate the analgesic effects of cannabinoids on colorectal distension induced visceral pain in rodents. (full – 2007)

GPR55: signaling pathways and functions (abst – 2007)

GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current (full - 2008)

Interactions of the G protein-coupled receptor-associated sorting proteins (GASP) 1 and 2 with the novel cannabinoid receptor GPR55 (abst – 2008)

The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo (full - 2009)

Receptors for acylethanolamides-GPR55 and GPR119. (full – 2009)

Endocannabinoids and the gastrointestinal tract: what are the key questions? (full - 2009)

Cannabinoid receptor ligands as potential anticancer agents--high hopes for new therapies? (full – 2009)

Endocannabinoid-mediated control of synaptic transmission. (full – 2009)

The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. (full – 2009)

Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. (full – 2009)

Receptors for acylethanolamides-GPR55 and GPR119. (full – 2009)

Is GPR55 an anandamide receptor? (abst – 2009)

The enigmatic pharmacology of GPR55. (abst – 2009)

Mode of action of cannabinoids on nociceptive nerve endings. (abst – 2009)

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 (full – 2010)

GPR55 ligands promote receptor coupling to multiple signalling pathways. (full – 2010)

A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. (full – 2010)

Pharmacological characterization of GPR55, a putative cannabinoid receptor. (full – 2010)

Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. (full– 2010)

GPR55: Current Knowledge and Future Perspectives of a Purported "Type-3" Cannabinoid Receptor. (abst - 2010)

Cannabinoids and the gut: new developments and emerging concepts (abst – 2010)

Cannabinoids and Bone: Friend or Foe? (abst – 2010)

Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. (full – 2011)

The Type 2 Cannabinoid Receptor Regulates Bone Mass and Ovariectomy-Induced Bone Loss by Affecting Osteoblast Differentiation and Bone Formation (full – 2011)

The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. (full – 2011)

Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55. (full – 2011)

Screening for Selective Ligands for GPR55. (full – 2011)

GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. (full – 2011)

New blood brothers: the GPR55 and CB2 partnership (full – 2011)

A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. (full – 2011)

The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. (full – 2011)

What is the natural ligand of GPR55? (full – 2011)

A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. (full – 2011)

L-α-lysophosphatidylinositol meets GPR55: a deadly relationship. (abst – 2011)

Pharmacology, Signaling and Physiological Relevance of the G Protein-coupled Receptor 55. (abst – 2011)

The GPCR - associated sorting protein 1 regulates ligand-induced downregulation of GPR55. (abst – 2011)

Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor. (abst – 2011)

The novel cannabinoid receptor GPR55, inhibits cholangiocarcinoma growth (abst – 2011)

Modulation of the novel cannabinoid receptor - GPR55 - during rat fetoplacental development (abst – 2011)

The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. (abst – 2011)

Pharmacology, signaling and physiological relevance of the G protein-coupled receptor 55. (abst – 2011)

Functional polymorphism in the GPR55 gene is associated with anorexia nervosa. (abst – 2011)

The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. (abst – 2011)

Off-Target Cannabinoid Effects Mediated by GPR55. (full – 2012)

Role of cannabinoids in the regulation of bone remodeling (full – 2012)

The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. (full – 2012)

Effects of Palmitoylethanolamide on Aqueous Humor Outflow. (full – 2012)

The Endocannabinoids Anandamide and Virodhamine Modulate the Activity of the Candidate Cannabinoid Receptor GPR55. (full – 2012)

Cannabinoid 2 (CB2) Receptor Involvement in the Down-regulation but not Upregulation of Serum IgE Levels in Immunized Mice. (full – 2012)

The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. (full – 2012)

Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain. (full – 2012)

G-Protein-Coupled Receptors in Intestinal Chemosensation (full – 2012)

Evidence for the Putative Cannabinoid Receptor (GPR55)-Mediated Inhibitory Effects on Intestinal Contractility in Mice. (full – 2012)

The atypical cannabinoid O-1602 increases hind paw sensitisation in the chronic constriction injury model of neuropathic pain. (abst – 2012)

The interaction between intrathecal administration of low doses of palmitoylethanolamide and AM251 in formalin-induced pain related behavior and spinal cord IL1-β expression in rats. (abst – 2012)

GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. (abst – 2012)

A homology modeling study toward the understanding of three-dimensional structure and putative pharmacological profile of the G-protein coupled receptor GPR55. (abst – 2012)

The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors (full – 2013)

GPR55, a G-Protein Coupled Receptor for Lysophosphatidylinositol, Plays a Role in Motor Coordination. (full – 2013)

Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. (full – 2013)

Role of endogenous cannabinoid system in the gut. (full – 2013)

A potential role for GPR55 in gastrointestinal functions. (full – 2013)

The Natural Product Magnolol as a Lead Structure for the Development of Potent Cannabinoid Receptor Agonists (full – 2013)

A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. (full – 2013)

Rod Photoreceptors Express GPR55 in the Adult Vervet Monkey Retina. (full – 2013)

Genetic Background Can Result in a Marked or Minimal Effect of Gene Knockout (GPR55 and CB2 Receptor) in Experimental Autoimmune Encephalomyelitis Models of Multiple Sclerosis. (full – 2013)

Magnolia extract, magnolol and metabolites: activation of cannabinoid CB2 receptors and blockade of the related GPR55 (full – 2013)

A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. (full – 2013)

The Endocannabinoid System and Sex Steroid Hormone-Dependent Cancers (full – 2013)

A potential role for GPR55 in gastrointestinal functions. (full – 2013)

Orphan G protein receptor GPR55 as an emerging target in cancer therapy and management. (full – 2013)

GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors (link to PDF – 2013)

The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55. (abst – 2013)

Cannabinoid receptor modulation of the endothelial cell inflammatory response (abst – 2013)

Regulation of cell proliferation by GPR55/cannabinoid receptors using (R,R')-4’-methoxy-1-naphthylfenoterol in rat C6 glioma cell line (abst – 2013)

Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice. (abst – 2013)

The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microgliadependent neuroprotection after excitotoxic lesion. (abst – 2013)

(R,R’)-4’-methoxy-1-naphthylfenoterol Inhibits GPR55 signaling and the modulation of motility in human cancer cells (abst – 2013)

Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice. (abst – 2013)

Anticancer activity of anandamide in human cutaneous melanoma cells. (abst – 2013)

Differential expression and functional role of cannabinoid genes in alcohol users. (abst – 2013)

Identification of the GPR55 Antagonist Binding Site Using a Novel Set of High Potency GPR55 Selective Ligands. (abst – 2013)

Increase of mesenchymal stem cell migration by Cannabidiol via activation of p42/44 MAPK. (abst – 2013)

(R,R')-4'-Methoxy-1-naphthylfenoterol Targets GPR55-mediated Ligand Internalization and Impairs Cancer Cell Motility. (abst – 2013)

Regulation of GPR55 in rat white adipose tissue and serum LPI by nutritional status, gestation, gender and pituitary factors. (abst – 2013)

The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. (full – 2014)

Vascular targets for cannabinoids: animal and human studies. (full – 2014)

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders (full – 2014)

CB2 Receptor Activation Inhibits Melanoma Cell Transmigration through the Blood-Brain Barrier. (full – 2014)

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. (abst – 2014)

Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease. (abst – 2014)

CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum. (abst – 2014)

GPR55: From orphan to metabolic regulator? (abst – 2014)

Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signaling. (abst – 2014)

Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling (abst – 2014)

The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. (abst – 2014)

UEA research reveals how cannabis compound could slow tumour growth (news – 2014)

How marijuana shrinks cancerous tumours (news – 2014)

October 1, 2014 at 8:18 AM Flag Quote & Reply

This topic is closed, no additional posts are allowed.